188 related articles for article (PubMed ID: 18629572)
41. Comparative effects of densitometric and absolute fracture risk classification systems on projected intervention rates in postmenopausal women.
Leslie WD; Siminoski K; Brown JP
J Clin Densitom; 2007; 10(2):124-31. PubMed ID: 17485029
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.
Mueller D; Gandjour A
Value Health; 2009; 12(8):1106-17. PubMed ID: 19706151
[TBL] [Abstract][Full Text] [Related]
43. Kidney Function and Cardiovascular Events in Postmenopausal Women: The Impact of Race and Ethnicity in the Women's Health Initiative.
Arce CM; Rhee JJ; Cheung KL; Hedlin H; Kapphahn K; Franceschini N; Kalil RS; Martin LW; Qi L; Shara NM; Desai M; Stefanick ML; Winkelmayer WC;
Am J Kidney Dis; 2016 Feb; 67(2):198-208. PubMed ID: 26337132
[TBL] [Abstract][Full Text] [Related]
44. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.
Drieling RL; LaCroix AZ; Beresford SA; Boudreau DM; Kooperberg C; Chlebowski RT; Gass M; Crandall CJ; Womack CR; Heckbert SR
Menopause; 2016 Nov; 23(11):1168-1175. PubMed ID: 27433859
[TBL] [Abstract][Full Text] [Related]
45. Association of pelvic organ prolapse and fractures in postmenopausal women: analysis of baseline data from the Women's Health Initiative Estrogen Plus Progestin trial.
Pal L; Hailpern SM; Santoro NF; Freeman R; Barad D; Kipersztok S; Barnabei VM; Wassertheil-Smoller S
Menopause; 2008; 15(1):59-66. PubMed ID: 18257143
[TBL] [Abstract][Full Text] [Related]
46. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
[TBL] [Abstract][Full Text] [Related]
47. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
[TBL] [Abstract][Full Text] [Related]
48. Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50.
Naves M; Díaz-López JB; Gómez C; Rodríguez-Rebollar A; Cannata-Andía JB
Osteoporos Int; 2005 Dec; 16(12):2013-7. PubMed ID: 16091836
[TBL] [Abstract][Full Text] [Related]
49. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative.
Chen Z; Maricic M; Aragaki AK; Mouton C; Arendell L; Lopez AM; Bassford T; Chlebowski RT
Osteoporos Int; 2009 Apr; 20(4):527-36. PubMed ID: 18766294
[TBL] [Abstract][Full Text] [Related]
50. Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
McClung MR; Williams GC; Hattersley G; Fitzpatrick LA; Wang Y; Miller PD
Calcif Tissue Int; 2018 Jun; 102(6):627-633. PubMed ID: 29285549
[TBL] [Abstract][Full Text] [Related]
51. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study.
Bonds DE; Larson JC; Schwartz AV; Strotmeyer ES; Robbins J; Rodriguez BL; Johnson KC; Margolis KL
J Clin Endocrinol Metab; 2006 Sep; 91(9):3404-10. PubMed ID: 16804043
[TBL] [Abstract][Full Text] [Related]
52. Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA).
Barrett-Connor E; Sajjan SG; Siris ES; Miller PD; Chen YT; Markson LE
Osteoporos Int; 2008 May; 19(5):607-13. PubMed ID: 18058055
[TBL] [Abstract][Full Text] [Related]
53. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
54. Postmenopausal weight change and incidence of fracture: post hoc findings from Women's Health Initiative Observational Study and Clinical Trials.
Crandall CJ; Yildiz VO; Wactawski-Wende J; Johnson KC; Chen Z; Going SB; Wright NC; Cauley JA
BMJ; 2015 Jan; 350():h25. PubMed ID: 25627698
[TBL] [Abstract][Full Text] [Related]
55. Epidemiology of fracture risk in the Women's Health Initiative.
Jackson RD; Donepudi S; Mysiw WJ
Curr Osteoporos Rep; 2008 Dec; 6(4):155-61. PubMed ID: 19032926
[TBL] [Abstract][Full Text] [Related]
56. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
Yao S; Laurent CA; Roh JM; Lo J; Tang L; Hahn T; Ambrosone CB; Kushi LH; Kwan ML
Breast Cancer Res Treat; 2020 Feb; 180(1):187-195. PubMed ID: 31912328
[TBL] [Abstract][Full Text] [Related]
57. Association between low lean body mass and osteoporotic fractures after menopause.
Capozza RF; Cure-Cure C; Cointry GR; Meta M; Cure P; Rittweger J; Ferretti JL
Menopause; 2008; 15(5):905-13. PubMed ID: 18520697
[TBL] [Abstract][Full Text] [Related]
58. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment.
Feldstein AC; Nichols GA; Elmer PJ; Smith DH; Aickin M; Herson M
J Bone Joint Surg Am; 2003 Dec; 85(12):2294-302. PubMed ID: 14668497
[TBL] [Abstract][Full Text] [Related]
59. Defining ethnic and racial differences in osteoporosis and fragility fractures.
Cauley JA
Clin Orthop Relat Res; 2011 Jul; 469(7):1891-9. PubMed ID: 21431462
[TBL] [Abstract][Full Text] [Related]
60. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
